Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 461 participants.
Also called NCT02284893
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 461 participants
- Sponsor
- Registry
-
NCT02284893 -
2014-001102-17
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Hungary, Mexico, Poland, Romania, South Africa
- Registry status
- Completed
Technical summary
Registry record NCT02284893. Randomized; triple masking; primary purpose treatment. Start 2014-09-09 (actual); primary completion 2016-09-20 (actual). Results posted on 2018-06-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo matching with Saxagliptin
- Intervention (Drug)
- Placebo matching with Dapagliflozin
- Intervention (Drug)
- Placebo matching with Sitagliptin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02284893- Content hash
746cb4ae37f2a42158aecfa70cb95c3c18f21a2ba38b6b8bc035e4e30319a7c0